Regulation & law · 03/12/1996Updated: 10/18/2026 · 1 min read

FDA Withdraws Approval for Cyclospasmol Due to Lack of Efficacy

The FDA Commissioner has withdrawn approval for Cyclospasmol, a drug for treating intermittent claudication and cognitive dysfunction in Alzheimer's patients, after determining it was not effective based on available studies. The decision follows an Administrative Law Judge's finding that the drug lacked sufficient evidence to support its intended uses.